<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02435212</url>
  </required_header>
  <id_info>
    <org_study_id>CICL670F2202</org_study_id>
    <secondary_id>2013-004739-55</secondary_id>
    <nct_id>NCT02435212</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-&lt;18 Years Old) With Iron Overload</brief_title>
  <official_title>A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients With Iron Overload</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, multicenter, two arm, phase II study to evaluate treatment
      compliance and change in serum ferritin of a deferasirox granule formulation and a
      deferasirox DT formulation in children and adolescents aged ≥ 2 and &lt; 18 years at enrollment
      with any transfusion-dependent anemia requiring chelation therapy due to iron overload, to
      demonstrate the effect of improved compliance on iron burden.

      Randomization will be stratified by age groups (2 to &lt;10 years, 10 to &lt;18 years) and prior
      iron chelation therapy (Yes/ No). There will be two study phases which include a 1 year core
      phase where patients will be randomized to a 48 week treatment period to either Deferasirox
      DT or granules, and an optional extension phase where all patients will receive the granules
      up to 5 years. Patients who demonstrated benefit to granules or DT in the core phase, and/or
      express the wish to continue in the optional extension phase on granules, will be offered
      this possibility until there is local access to the new formulation (granules or FCT) or up
      to 5 years, whichever occurs first.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2015</start_date>
  <completion_date type="Anticipated">March 29, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 29, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compliance (using stick/pack tablet count).</measure>
    <time_frame>48 weeks</time_frame>
    <description>Evaluate patient compliance measured by stick pack/tablet count in ICT naïve patients during core phase.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum ferritin in ICT naive patients.</measure>
    <time_frame>Baseline, 48 weeks</time_frame>
    <description>The comparison of means between the two treatment arms of change from baseline to week 48 of treatment in serum ferritin in pediatric ICT naïve patients with iron overload.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Domain scores of treatment satisfaction and palatability over time</measure>
    <time_frame>From baseline to 48 weeks</time_frame>
    <description>To evaluate both formulations on patient satisfaction and palatability using Patient / Observer Reported Outcomes (PRO/ObsRO) questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall safety, as measured by frequency and severity of adverse</measure>
    <time_frame>From Baseline to 48 weeks</time_frame>
    <description>This includes active monitoring for renal toxicity; including renal failure, hepatic toxicity; including hepatic failure, and gastrointestinal hemorrhage), and changes in laboratory values from baseline (serum creatinine, creatinine clearance, ALT, AST, RBC and WBC). In addition, vital signs, physical, ophthalmological, audiometric, cardiac, and growth and development evaluations will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of dosing instructions deviations ('Compliance', using a questionnaire)</measure>
    <time_frame>From Baseline to 48 weeks</time_frame>
    <description>This includes doses missed/not taken at the same time every day, to evaluate the compliance using a daily PRO/ObsRO questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose deferasirox concentrations in all patients</measure>
    <time_frame>at Weeks 1, 3, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, and 45 (13 samples)</time_frame>
    <description>The pre-dose concentration by incident dose will be plotted for Week 1, Week 3, Week 5, Week 9, Week 13, Week 17, Week 21, Week 25, Week 29, Week 33, Week, 37, Week 41 and Week 45 based on data from all patients. Pre-dose PK data from all patients will be analyzed to support the assessment of compliance.Predicted individual concentrations derived from the compartmental model will be compared to respective observed pre-dose concentrations. Distributions of the difference between predicted and observed values will be shown graphically by boxplots for both treatment groups and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-dose deferasirox concentrations between 2 and 4 hours post-dose at Weeks 5 and 9</measure>
    <time_frame>Week 5, Week 9</time_frame>
    <description>post-dose PK data to be analyzed along with pre-dose PK data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum ferritin in ICT naïve and pretreated patients</measure>
    <time_frame>Baseline, 48 weeks</time_frame>
    <description>To evaluate absolute and relative change from baseline in serum ferritin in both populations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK/PD relationship</measure>
    <time_frame>From Baseline to 48 weeks</time_frame>
    <description>To explore exposure-response relationships for measures of safety and effectiveness: serum creatinine change from baseline, notable serum creatinine values, serum creatinine clearance change from baseline and notable serum creatinine clearance categories, serum ferritin change from baseline, in relationship to derived PK parameters for pre- and post-dose deferasirox concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess additional safety, as measured by frequency and severity of adverse for granules during extension phase</measure>
    <time_frame>From Baseline to 305 weeks</time_frame>
    <description>This includesactive monitoring for renal toxicity; including renal failure, hepatic toxicity; including hepatic failure, and gastrointestinal hemorrhage), and changes in laboratory values from baseline (serum creatinine, creatinine clearance, ALT, AST, RBC and WBC). In addition, vital signs, physical, ophthalmological, audiometric, and growth and development evaluations will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Transfusion-dependent Anemia</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferasirox granule formulation</intervention_name>
    <description>Deferasirox granules will be provided as stick packs containing 90 mg, 180 mg and 360 mg granules for oral use.</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>ICL670</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferasirox DT formulation</intervention_name>
    <description>Deferasirox DT will be provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Exjade, ICL670</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent/assent before any study-specific procedures. Consent will be
             obtained from parent(s) or legal guardians. Investigators will also obtain assent of
             patients according to local guidelines.

          -  Male and female children and adolescents aged ≥ 2 and &lt; 18 years. [France: Male and
             female children and adolescent aged ≥ 2 and &lt; 18 years old, however children aged ≥ 2
             and ≤ 6years can be enrolled only when deferoxamine treatment is contraindicated or
             inadequate in these patients as per investigator decision. Applicable to core phase
             only. Once in the core phase patients can turn 18 years and still be considered
             eligible, also for participation in the optional extension phase.

          -  Any transfusion-dependent anemia associated with iron overload requiring iron
             chelation therapy and with a history of transfusion of approximately 20 PRBC units and
             a treatment goal to reduce iron burden (300mL PRBC = 1 unit in adults whereas 4 ml/kg
             PRBC is considered 1 unit for children).

          -  Serum ferritin &gt; 1000 ng/mL, measured at screening Visit 1 and screening Visit 2 (the
             mean value will be used for eligibility criteria).

          -  Patient has to have participated and completed the 48 weeks core phase treatment as
             per protocol (For optional extension phase eligibility only).

          -  Patient needs to meet all the eligibility criteria (inclusion and exclusion) as
             defined in the core phase at Visit 17 (For optional extension phase eligibility only).

        Exclusion Criteria:

          -  Creatinine clearance below the contraindication limit in the locally approved
             prescribing information (using Schwartz formula) at screening visit 1 or screening
             visit 2.

          -  Serum creatinine &gt; 1.5 xULN at screening measured at screening Visit 1 and or
             screening Visit 2

          -  ALT and/or AST &gt; 3.0 x ULN at screening visit 1 or screening visit 2.

          -  (Criterion no longer applicable, removed as part of Amendment 1): Prior iron chelation
             therapy.

          -  Liver disease with severity of Child-Pugh class B or C.

          -  Significant proteinuria as indicated by a urinary protein/creatinine ratio &gt; 0.5 mg/mg
             in a second morning urine sample at screening Visit 1 or screening Visit 2.

          -  Patients with significant impaired gastrointestinal (GI) function or GI disease that
             may significantly alter the absorption of oral deferasirox (e.g. ulcerative diseases,
             uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel
             resection).

        Other protocol-defined Inclusion/Exclusion may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Oakland Onc Dept</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynne Neumayr</last_name>
      <phone>510-428-3651</phone>
      <email>lneumayr@mail.cho.org</email>
    </contact>
    <investigator>
      <last_name>Ashutosh Lal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta Onc Dept</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Garrett</last_name>
      <phone>407-785-2025</phone>
      <email>Katherine.garrett@choa.org</email>
    </contact>
    <investigator>
      <last_name>Maa-Ohui Quarmyne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital of Chicago Onc Dept</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauline Hess</last_name>
      <phone>312-227-4824</phone>
      <email>phess@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Alexis Thompson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College SC -</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniella H Stern</last_name>
      <phone>212-746-3446</phone>
      <email>das2075@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Sujit Sheth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital at Montefiore</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Filipelli</last_name>
      <phone>718-741-2384</phone>
      <email>jfilipelli@brany.com</email>
    </contact>
    <investigator>
      <last_name>Deepa Manwani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia Onc. Dept</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4399</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Hammond</last_name>
      <phone>267-426-5602</phone>
      <email>hammondjh@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Janet L. Kwiatkowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina Medical Uni of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily M. Warner</last_name>
      <email>warnere@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Sherron Jackson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital Memphis St Jude</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Carr</last_name>
      <email>teresa.carr@stjude.org</email>
    </contact>
    <investigator>
      <last_name>Jane Felipe Hankins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Univeristy Vanderbilt University Medical</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Currie</last_name>
      <email>Laura.currie@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Emmanuel J Volanakis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital Oncology Department</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Lakings</last_name>
      <phone>832-824-4825</phone>
      <email>axlaking@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Amber M Yates</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brussel</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1094</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orbassano</city>
        <state>TO</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Napoli</city>
        <zip>80132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hazmiyeh</city>
        <state>Beirut</state>
        <zip>PO Box 213</zip>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kuching</city>
        <state>Sarawak</state>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50589</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pulau Pinang</city>
        <zip>10990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muscat</city>
        <zip>123</zip>
        <country>Oman</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Panama City</city>
        <state>Republica de Panama</state>
        <country>Panama</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1100</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moskow</city>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok noi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muang</city>
        <state>Chiangmai</state>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tunis</city>
        <zip>1006</zip>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Lebanon</country>
    <country>Malaysia</country>
    <country>Oman</country>
    <country>Panama</country>
    <country>Philippines</country>
    <country>Russian Federation</country>
    <country>Thailand</country>
    <country>Tunisia</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Denmark</country>
  </removed_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2015</study_first_submitted>
  <study_first_submitted_qc>April 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2015</study_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>New formulation, deferasirox, chelation, iron overload, compliance, satisfaction, palatability, PRO, PK, safety, PK/PD, ICL670</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron Overload</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferasirox</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

